Mithramycin A (Synonyms: Mithramycin A) |
رقم الكتالوجGC15060
One-Click Copy Product Info
|
Mithramycin A is an antibiotic isolated from S. grieseus. As a selective inhibitor of specific protein 1 (Sp1), Mithramycin A binds to DNA sequences rich in GC, replacing the Sp1 transcription factor that binds to oncogenes, thereby inhibiting gene expression.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 18378-89-7
Sample solution is provided at 25 µL, 10mM.
Mithramycin A is an antibiotic isolated from S. grieseus [1]. As a selective inhibitor of specific protein 1 (Sp1), Mithramycin A binds to DNA sequences rich in GC, replacing the Sp1 transcription factor that binds to oncogenes, thereby inhibiting gene expression [2]. Mithramycin A has anti-tumor and neuroprotective effects [3].
In vitro, Mithramycin A (0-400nM, 24 hours) can dose-dependently inhibit the expression of GSTM2 protein in BFTC 905 and 5637 cells [4]. Mithramycin A (75μM; 24 hours) significantly increases the apoptosis of TNF-induced TF-1 cells, and the enhanced cytotoxicity of Mithramycin A on TNF occurs at the FADD level or its downstream position [5].
In vivo, Mithramycin A (0.2mg/kg/day; three times per week for 29 days; i.p.) significantly reduces the tumor volume of human cervical cancer cell xenograft mice and increases the number of TUNEL-positive cells in the tumor xenografts [6]. Mithramycin A (150μg/kg/day; 60 days; i.p.) treatment can effectively inhibit the Sp1 activation level in APPswe/PS1dE9 mice, significantly reduce the Aβ level and plaque load in the mouse brain, and reduce tau hyperphosphorylation, and increase synaptic markers [7].
References:
[1] Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR. Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. Pharmaceuticals (Basel). 2011;4(8):1183-1195.
[2] Choi ES, Nam JS, Jung JY, Cho NP, Cho SD. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014;4:7162.
[3] Sleiman SF, Langley BC, Basso M, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011;31(18):6858-6870.
[4] Shen CH, Wu JY, Wang SC, et al. The suppressive role of phytochemical-induced glutathione S-transferase Mu 2 in human urothelial carcinoma cells. Biomed Pharmacother. 2022;151:113102.
[5] Duverger V, Murphy AM, Sheehan D, et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer. 2004;90(10):2025-2031.
[6] Choi ES, Nam JS, Jung JY, Cho NP, Cho SD. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 2014;4:7162.
[7] Wei C, Zhang W, Zhou Q, et al. Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Neurochem Res. 2016;41(8):1924-1938.
| Cell experiment [1]: | |
|
Cell lines |
TF-1 cells |
|
Preparation Method |
For GM-CSF withdrawal experiments, TF-1 cells were washed twice in Hank's buffered saline solution, then resuspended in RPMI 1640 medium containing 10% FCS in the presence or absence of 75nM mithramycin. For combination experiments with TNF (20ng/ml), cells were maintained in complete medium and treated with Mithramycin A simultaneously to the different drugs. Collect the cells after 24 hours of co-culture. Cell cycle status and quantification of DNA fragmentation was performed by propidium iodide (PI) staining. DNA content was determined using a FACSCalibur flow cytometer. Quantification of apoptosis by phosphatidylserine exposure was assessed by annexin V staining using the Alexa Flour 488 kit according to the manufacturer's instruction. |
|
Reaction Conditions |
75μM; 24h |
|
Applications |
Mithramycin A increased apoptosis in TNF-induced TF-1 cells. The enhanced cytotoxic effect of Mithramycin A on TNF was observed at the FADD level or at its downstream location. |
| Animal experiment [2]: | |
|
Animal models |
Nude mouse (xenograft model) |
|
Preparation Method |
KB cells were suspended in sterile PBS and injected subcutaneously into the right flank of mice. Mice were randomized into two groups containing five mice each and treated with 0.2mg/kg/day of Mithramycin A (i.p.) three times per week for 29 days. Control mice received an equal volume of vehicle. After 29 days, bodies, organs and tumors were weighed and tumor volumes determined. Tumors were measured along the two diameter axis with calibers to allow calculation of tumor volume. |
|
Dosage form |
0.2mg/kg/day; three times per week for 29 days; i.p. |
|
Applications |
Mithramycin A significantly reduces the tumor volume in mice with human cervical cancer cell xenografts. |
|
References: |
|
| Cas No. | 18378-89-7 | SDF | |
| المرادفات | Mithramycin A | ||
| Chemical Name | (1S)-5-Deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy--D-arabino-hexopyranosyl)--D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl--D-ribo-hexopyranosyl-(1.fwdarw.3)-O-2,6-dideoxy--D-lyxo-hexopyranosyl-(1.fwdarw.3)-2,6-dideoxy--D-arabino-hexo | ||
| Canonical SMILES | CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O | ||
| Formula | C52H76O24 | M.Wt | 1085.16 |
| الذوبان | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml,PBS (pH 7.2): 2 mg/ml | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 921.5 μL | 4.6076 mL | 9.2152 mL |
| 5 mM | 184.3 μL | 921.5 μL | 1.843 mL |
| 10 mM | 92.2 μL | 460.8 μL | 921.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)